Bronchiolitis Obliterans
Conditions
Keywords
Bortezomib GVHD Bronchiolitis Obliterans
Brief summary
Approximately 10,000 allogeneic hematopoietic stem cell transplants (HSCT) are performed annually in the US for various indications. Bronchiolitis obliterans (BO) is the most common late noninfectious complication following allogeneic hematopoietic stem cell transplant. Prognosis of BO in the allogeneic HSCT setting is dismal and there are no therapies proven to be consistently effective. The exact incidence is not clear but may be as high as 30%2 . Risk factors include new or ongoing chronic graft versus host disease (cGVHD), age, antecedent obstructive airways disease and viral infections1. BO is characterized physiologically by progressive irreversible airflow obstruction and pathologically by luminal occlusion of the distal airways due to progressive scarring3. The pathogenesis is not completely understood but the cytokine transforming growth factor-beta 1 (TGF-b1), important for both tissue repair and fibrosis, is thought to play a pivotal role. Bortezomib, an FDA approved proteasomal inhibitor inhibits TGF-b1 signaling in vitro and protects against lung injury/fibrosis in bleomycin mouse model as well as in a mouse model for skin fibrosis. This is consistent with other data in the literature that proteasomal inhibition can prevent the development of fibrosis. Thus the investigators propose to test the safety, tolerability and efficacy of bortezomib in chronic pulmonary GVHD (BO).
Interventions
Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
Sponsors
Study design
Eligibility
Inclusion criteria
* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. * Male subject agrees to use an acceptable method for contraception for the duration of the study. * Day \>100 after allogeneic hematopoietic stem cell transplantation * Underlying cancer in remission * Decrease in FEV1 of ≥12% from the pre-transplant baseline (FEV1/FVC ratio \<0.8) * No evidence of acute infection * ANC \>1000 * Platelets \>50,000 * Age 18-70 * ECOG performance Status 0-2.
Exclusion criteria
* Patient has a platelet count of less than 50,000 within 14 days before enrollment. * Patient has an absolute neutrophil count of less 1000 within 14 days before enrollment. * Patient has a calculated or measured creatinine clearance of \< 20 ml/minute within 14 days before enrollment. * Patient has Grade 2 peripheral neuropathy within 14 days before enrollment. * Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant. * Patient has hypersensitivity to bortezomib, boron or mannitol. * Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum b-human chorionic gonadotropin (b-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. * Patient has received other investigational drugs with 14 days before enrollment * Serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Inability of give consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Pulmonary Function as Measured by Forced Expiratory Volume in 1 Second (FEV1) Decline | Mean time to diagnosis (from transplant to p-CGVHD ) of 3.36 years (+/- 1.88 years) and up to 18 weeks after baseline | FEV1 will be measured by spirometry assessments at baseline (pre-transplant baseline - prior to pulmonary chronic graft-versus-host disease (p-CGVHD)) during treatment (10 weeks) and at follow up visit 9 (at 12 weeks) and at follow up visit 10 (at 18 weeks) with patients having spirometry tested up to 6 times from screening to the end of the study. FEV1 is reported as slopes computed by dividing difference in FEV1 by time in months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Exercise Tolerance- 6 Minute Walk | Up to 18 weeks from baseline | Patients will have an exercise tolerance assessment defined as a 6 minute walk completed at cycle 1 (week 1) and cycle 2 (week 5) of treatment and visit 9 (12 weeks) and visit 10 (18 weeks). |
| Short Form (SF)-36 Health Survey | up to 18 weeks | This is a quality of life questionnaire which yields scores for 8 domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health). This questionnaire will be completed by patients on Visit 1 (week 1), Visit 5 (week 5), Visit 8 (week 8), Visit 9 (12 weeks), and Visit 10 (18 weeks). Questionnaires were scored per the scoring rules for the RAND 36-Item Health Survey (version 1.0) A high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered. |
Countries
United States
Participant flow
Recruitment details
The study opened for accrual on July 20, 2010 with an accrual goal of up to 20 evaluable patients. The first patient being enrolled on the study on October 7th 2010. The study was closed permanently on August 31 2015 before the accrual goal was met with 17 patients being treated on study.
Pre-assignment details
Patients were diagnosed with pulmonary Chronic Graft Verses Host Disease (p-CGVHD) after having undergone allogeneic hematopoietic stem cell transplant (HSCT). Patients were required to be less than 100 days post HSCT, with an absolute decrease of 12% or more in forced expiratory volume in 1 second (FEV1) from pre-transplant baseline.
Participants by arm
| Arm | Count |
|---|---|
| Bortezomib Patients will receive 2 cycles of Bortezomib (given weekly for 4 weeks) for a total of 8 doses of Bortezomib. Each cycle will consist of weekly bortezomib with a 2 week interval between cycles.
Bortezomib: Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib will be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle. | 17 |
| Total | 17 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Completed Follow up (Visit 9 and 10) | Other | 1 |
| Treatment With Bortezomib | Adverse Event | 2 |
| Treatment With Bortezomib | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Bortezomib |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 2 Participants |
| Age, Categorical Between 18 and 65 years | 15 Participants |
| Disease Acute Leukemia | 6 Participants |
| Disease Chronic Myelogenous Leukemia | 3 Participants |
| Disease Lymophoma | 4 Participants |
| Disease Myeloma | 2 Participants |
| Disease Other | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 14 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| lumonary Function Testing at time of pulmonary Chronic Graft-verses-host disease (pGVHD) Diagnosis FEV/FVC | 61 percentage STANDARD_DEVIATION 14 |
| lumonary Function Testing at time of pulmonary Chronic Graft-verses-host disease (pGVHD) Diagnosis Forced Expiratory Volume in 1 Second (FEV1) | 47 percentage STANDARD_DEVIATION 16 |
| lumonary Function Testing at time of pulmonary Chronic Graft-verses-host disease (pGVHD) Diagnosis Forced Vital Capacity (FVC) | 60 percentage STANDARD_DEVIATION 15 |
| Plumonary Function Testing (PFT) at time of transplant FEV/FVC | 81 percentage STANDARD_DEVIATION 5 |
| Plumonary Function Testing (PFT) at time of transplant Forced Expiratory Volume in 1 Second (FEV1) | 90 percentage STANDARD_DEVIATION 17 |
| Plumonary Function Testing (PFT) at time of transplant Forced Vital Capacity (FVC) | 89 percentage STANDARD_DEVIATION 18 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 15 Participants |
| Region of Enrollment United States | 17 participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 13 Participants |
| Sex Matching of Transplantation Female-female | 1 Participants |
| Sex Matching of Transplantation Female-male | 3 Participants |
| Sex Matching of Transplantation male-female | 5 Participants |
| Sex Matching of Transplantation male-male | 8 Participants |
| Time from transplant to pGVHD diagnosis | 3.36 years STANDARD_DEVIATION 1.88 |
| Transplant Type Matched Sibling | 12 Participants |
| Transplant Type Matched unrelated | 4 Participants |
| Transplant Type Mini matched unrelated | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 17 |
| other Total, other adverse events | 17 / 17 |
| serious Total, serious adverse events | 3 / 17 |
Outcome results
Change in Pulmonary Function as Measured by Forced Expiratory Volume in 1 Second (FEV1) Decline
FEV1 will be measured by spirometry assessments at baseline (pre-transplant baseline - prior to pulmonary chronic graft-versus-host disease (p-CGVHD)) during treatment (10 weeks) and at follow up visit 9 (at 12 weeks) and at follow up visit 10 (at 18 weeks) with patients having spirometry tested up to 6 times from screening to the end of the study. FEV1 is reported as slopes computed by dividing difference in FEV1 by time in months.
Time frame: Mean time to diagnosis (from transplant to p-CGVHD ) of 3.36 years (+/- 1.88 years) and up to 18 weeks after baseline
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Bortezomib | Change in Pulmonary Function as Measured by Forced Expiratory Volume in 1 Second (FEV1) Decline | Prior to diagnosis of p-CGVHD | -1.06 percentage per month |
| Bortezomib | Change in Pulmonary Function as Measured by Forced Expiratory Volume in 1 Second (FEV1) Decline | During Treatment with Bortezomib | -0.25 percentage per month |
Exercise Tolerance- 6 Minute Walk
Patients will have an exercise tolerance assessment defined as a 6 minute walk completed at cycle 1 (week 1) and cycle 2 (week 5) of treatment and visit 9 (12 weeks) and visit 10 (18 weeks).
Time frame: Up to 18 weeks from baseline
Population: Data was collected but not analyzed due to the study closing before accrual was met. Below is data on how many patients started 6 minute walk and how many patients stopped before reaching 6 minutes at each time point is shown below.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Cycle 1 (Visit 1): Started 6 Minute walk | 13 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Cycle 1 (Visit 1): Stopped before 6 minutes | 3 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Cycle 1(Visit 1):Declined walk | 0 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Cycle 2 (Visit 5) : Started 6 Minute walk | 3 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Cycle 2 (Visit 5) : Stopped before 6 minutes | 0 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Cycle 2(Visit 5):Declined walk | 0 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Follow up/Visit 9: Started 6 Minute walk | 6 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Follow up/Visit 9 : Stopped before 6 minutes | 1 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Follow up/Visit 9: Declined walk | 1 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Follow up/Visit 10 : Started 6 Minute walk | 5 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Follow up/Visit 10 : Stopped before 6 minutes | 1 participants |
| Bortezomib | Exercise Tolerance- 6 Minute Walk | Follow up/Visit 10: Declined walk | 1 participants |
Short Form (SF)-36 Health Survey
This is a quality of life questionnaire which yields scores for 8 domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health). This questionnaire will be completed by patients on Visit 1 (week 1), Visit 5 (week 5), Visit 8 (week 8), Visit 9 (12 weeks), and Visit 10 (18 weeks). Questionnaires were scored per the scoring rules for the RAND 36-Item Health Survey (version 1.0) A high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered.
Time frame: up to 18 weeks
Population: Data was collected but not analyzed. Averages for each patient at each timepoint are shown below. N/a is shown for timepoints where data was not collected.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Emotional Well-being : Visit 1 | 88 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-physical : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-physical : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Physical Functioning : Visit 1 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Physical Functioning : Visit 5 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Physical Functioning : Visit 8 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Physical Functioning : Visit 9 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Physical Functioning : Visit 10 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Role-physcial : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Role-physcial : Visit 5 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Role-physcial : Visit 8 | 66.67 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Role-physcial : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Role-physcial : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Role-emotional : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Role-emotional : Visit 5 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Role-emotional : Visit 8 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Role-emotional : Visit 9 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Role-emotional : Visit 10 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Energy/fatigue : Visit 1 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Energy/fatigue : Visit 5 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Energy/fatigue : Visit 8 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Energy/fatigue : Visit 9 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Energy/fatigue : Visit 10 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 : Emotional Well-being : Visit 1 | 52 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 : Emotional Well-being : Visit 5 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 : Emotional Well-being : Visit 8 | 52 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 : Emotional Well-being : Visit 9 | 92 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 : Emotional Well-being : Visit 10 | 92 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Social Functioning : Visit 1 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Social Functioning : Visit 5 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Social Functioning : Visit 8 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Social Functioning : Visit 9 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: Social Functioning : Visit 10 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Pain : Visit 1 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Pain : Visit 5 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Pain : Visit 8 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Pain : Visit 9 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8 Pain : Visit 10 | 90 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: General Health : Visit 1 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: General Health : Visit 5 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: General Health : Visit 8 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: General Health : Visit 9 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #8: General Health : Visit 10 | 65 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Physical Functioning : Visit 1 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Physical Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Physical Functioning : Visit 8 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Physical Functioning : Visit 9 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Physical Functioning : Visit 10 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-physical : Visit 9 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-physical : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-emotional : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-emotional : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-emotional : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Role-emotional : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Energy/fatigue : Visit 1 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Energy/fatigue : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Energy/fatigue : Visit 8 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Energy/fatigue : Visit 9 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Energy/fatigue : Visit 10 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Emotional Well-being : Visit 1 | 84 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Emotional Well-being : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Emotional Well-being : Visit 8 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Emotional Well-being : Visit 9 | 92 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Emotional Well-being : Visit 10 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Social Functioning : Visit 1 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Social Functioning : Visit 8 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Social Functioning : Visit 9 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Social Functioning : Visit 10 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Pain : Visit 1 | 77.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Pain : Visit 8 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Pain : Visit 9 | 77.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: Pain : Visit 10 | 67.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: General Health : Visit 1 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: General Health : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: General Health : Visit 8 | 31.25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: General Health : Visit 9 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #9: General Health : Visit 10 | 56.25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Physical Functioning : Visit 1 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Physical Functioning : Visit 5 | 90 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Physical Functioning : Visit 8 | 83.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Physical Functioning : Visit 9 | 85 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Physical Functioning : Visit 10 | 85 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-physical : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-physical : Visit 5 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-physical : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-physical : Visit 9 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-physical : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-emotional : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-emotional : Visit 5 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-emotional : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-emotional : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Role-emotional : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Energy/fatigue : Visit 1 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Energy/fatigue : Visit 5 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Energy/fatigue : Visit 8 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Energy/fatigue : Visit 9 | 65 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Energy/fatigue : Visit 10 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Emotional Well-being : Visit 1 | 88 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Emotional Well-being : Visit 5 | 84 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Emotional Well-being : Visit 8 | 84 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Emotional Well-being : Visit 9 | 92 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10: Emotional Well-being : Visit 10 | 92 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 : Social Functioning : Visit 1 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 : Social Functioning : Visit 5 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 : Social Functioning : Visit 8 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 : Social Functioning : Visit 9 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 : Social Functioning : Visit 10 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Pain : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Pain : Visit 5 | 77.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Pain : Visit 8 | 77.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Pain : Visit 9 | 77.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Pain : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Visit 1 : General Health : Visit 1 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Visit 1 : General Health : Visit 5 | 65 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Visit 1 : General Health : Visit 8 | 65 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Visit 1 : General Health : Visit 9 | 65 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #10 Visit 1 : General Health : Visit 10 | 65 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Physical Functioning : Visit 1 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Physical Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Physical Functioning : Visit 8 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Physical Functioning : Visit 9 | 5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Physical Functioning : Visit 10 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-physical : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-physical : Visit 8 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-physical : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-physical : Visit 10 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-emotional : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-emotional : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-emotional : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Role-emotional : Visit 10 | 66.67 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Energy/fatigue : Visit 1 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Energy/fatigue : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Energy/fatigue : Visit 8 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Energy/fatigue : Visit 9 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Energy/fatigue : Visit 10 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Emotional Well-being : Visit 1 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Emotional Well-being : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Emotional Well-being : Visit 8 | 84 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Emotional Well-being : Visit 9 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Emotional Well-being : Visit 10 | 68 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Social Functioning : Visit 1 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Social Functioning : Visit 8 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Social Functioning : Visit 9 | 37.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Social Functioning : Visit 10 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Pain : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Pain : Visit 8 | 22.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Pain : Visit 9 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 Visit 1 : Pain : Visit 10 | 22.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 General Health : Visit 1 | 5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 General Health : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 General Health : Visit 8 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 General Health : Visit 9 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #11 General Health : Visit 10 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Physical Functioning : Visit 1 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Physical Functioning : Visit 5 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Physical Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Physical Functioning : Visit 9 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Physical Functioning : Visit 10 | 44.44 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-physical : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-physical : Visit 5 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-physical : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-physical : Visit 9 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-physical : Visit 10 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-emotional : Visit 1 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-emotional : Visit 5 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-emotional : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-emotional : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Role-emotional : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Energy/fatigue : Visit 1 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Energy/fatigue : Visit 5 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Energy/fatigue : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Energy/fatigue : Visit 9 | 65 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Energy/fatigue : Visit 10 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Emotional Well-being : Visit 1 | 68 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Emotional Well-being : Visit 5 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Emotional Well-being : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Emotional Well-being : Visit 9 | 72 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Emotional Well-being : Visit 10 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Social Functioning : Visit 1 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Social Functioning : Visit 5 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Social Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Social Functioning : Visit 9 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Social Functioning : Visit 10 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Pain : Visit 1 | 77.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Pain : Visit 5 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Pain : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Pain : Visit 9 | 67.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 Pain : Visit 10 | 77.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 General Health : Visit 1 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 General Health : Visit 5 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 General Health : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 General Health : Visit 9 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #12 General Health : Visit 10 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt#13 Physical Functioning : Visit 1 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt#13 Physical Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt#13 Physical Functioning : Visit 8 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt#13 Physical Functioning : Visit 9 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt#13 Physical Functioning : Visit 10 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-physical : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-physical : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-physical : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-physical : Visit 10 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-emotional : Visit 1 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-emotional : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-emotional : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Role-emotional : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Energy/fatigue : Visit 1 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Energy/fatigue : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Energy/fatigue : Visit 8 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Energy/fatigue : Visit 9 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Energy/fatigue : Visit 10 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Emotional Well-being : Visit 1 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Emotional Well-being : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Emotional Well-being : Visit 8 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Emotional Well-being : Visit 9 | 64 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Emotional Well-being : Visit 10 | 72 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Social Functioning : Visit 1 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Social Functioning : Visit 8 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Emotional Well-being : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Social Functioning : Visit 9 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Social Functioning : Visit 10 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Social Functioning : Visit 1 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Social Functioning : Visit 5 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Pain : Visit 1 | 67.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Social Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Social Functioning : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Pain : Visit 8 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Pain : Visit 8 | 32.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Pain : Visit 9 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Pain : Visit 9 | 32.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 Pain : Visit 10 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Pain : Visit 10 | 32.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 General Health : Visit 1 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 General Health : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 General Health : Visit 8 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 General Health : Visit 9 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #13 General Health : Visit 10 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Physical Functioning : Visit 1 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Physical Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Physical Functioning : Visit 8 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Physical Functioning : Visit 9 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Physical Functioning : Visit 10 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-physical : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-physical : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-physical : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-physical : Visit 10 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-emotional : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-emotional : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-emotional : Visit 9 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Role-emotional : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Energy/fatigue : Visit 1 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Physical Functioning : Visit 1 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Physical Functioning : Visit 5 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Physical Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Physical Functioning : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Physical Functioning : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-physical : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-physical : Visit 5 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-physical : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-physical : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-physical : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-emotional : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-emotional : Visit 5 | 66.67 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-emotional : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-emotional : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Role-emotional : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Energy/fatigue : Visit 1 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Energy/fatigue : Visit 5 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Energy/fatigue : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Energy/fatigue : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Energy/fatigue : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Emotional Well-being : Visit 1 | 88 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Emotional Well-being : Visit 5 | 84 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Emotional Well-being : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Emotional Well-being : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Social Functioning : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Pain : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Pain : Visit 5 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Pain : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Pain : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 Pain : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 General Health : Visit 1 | 65 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 General Health : Visit 5 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 General Health : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 General Health : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #01 General Health : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Physical Functioning : Visit 1 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Physical Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Physical Functioning : Visit 8 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Physical Functioning : Visit 9 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Physical Functioning : Visit 10 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-physical : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-physical : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-physical : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-physical : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-emotional : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-emotional : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-emotional : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Role-emotional : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Energy/fatigue : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Energy/fatigue : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Energy/fatigue : Visit 8 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Energy/fatigue : Visit 9 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Energy/fatigue : Visit 10 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Emotional Well-being : Visit 1 | 84 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Emotional Well-being : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Emotional Well-being : Visit 8 | 88 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Emotional Well-being : Visit 9 | 92 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Emotional Well-being : Visit 10 | 76 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Social Functioning : Visit 1 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Social Functioning : Visit 8 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Social Functioning : Visit 9 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Social Functioning : Visit 10 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Pain : Visit 1 | 32.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Pain : Visit 8 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Pain : Visit 9 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 Pain : Visit 10 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 General Health : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 General Health : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 General Health : Visit 8 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 General Health : Visit 9 | 31.25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #2 General Health : Visit 10 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Physical Functioning : Visit 1 | 16.67 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Physical Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Physical Functioning : Visit 8 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Physical Functioning : Visit 9 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Physical Functioning : Visit 10 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-physical : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-physical : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-physical : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-physical : Visit 10 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-emotional : Visit 1 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-emotional : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-emotional : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Role-emotional : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Energy/fatigue : Visit 1 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Energy/fatigue : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Energy/fatigue : Visit 8 | 5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Energy/fatigue : Visit 9 | 5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Energy/fatigue : Visit 10 | 5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Emotional Well-being : Visit 1 | 88 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Emotional Well-being : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Emotional Well-being : Visit 8 | 68 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Emotional Well-being : Visit 9 | 68 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3: Emotional Well-being : Visit 10 | 72 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : Social Functioning : Visit 1 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : Social Functioning : Visit 8 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : Social Functioning : Visit 9 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : Social Functioning : Visit 10 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Pain : Visit 1 | 90 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Pain : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Pain : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 Pain : Visit 10 | 90 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : General Health : Visit 1 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : General Health : Visit 5 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : General Health : Visit 8 | 31.25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : General Health : Visit 9 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #3 : General Health : Visit 10 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Physical Functioning : Visit 1 | 45 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Physical Functioning : Visit 5 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Physical Functioning : Visit 8 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Physical Functioning : Visit 9 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Physical Functioning : Visit 10 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-physcial : Visit 1 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-physcial : Visit 5 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-physcial : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-physcial : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-physcial : Visit 10 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-emotional : Visit 1 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-emotional : Visit 5 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-emotional : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-emotional : Visit 9 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Role-emotional : Visit 10 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Energy/fatigue : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Energy/fatigue : Visit 5 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Energy/fatigue : Visit 8 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Energy/fatigue : Visit 9 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Energy/fatigue : Visit 10 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Emotional Well-being : Visit 1 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Emotional Well-being : Visit 5 | 56 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Emotional Well-being : Visit 8 | 72 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Emotional Well-being : Visit 9 | 66.67 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Emotional Well-being : Visit 10 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Social Functioning : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Social Functioning : Visit 5 | 37.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Social Functioning : Visit 8 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Social Functioning : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Social Functioning : Visit 10 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Pain : Visit 1 | 22.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Pain : Visit 5 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Pain : Visit 8 | 67.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Pain : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : Pain : Visit 10 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : General Health : Visit 1 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : General Health : Visit 5 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : General Health : Visit 8 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : General Health : Visit 9 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #4 : General Health : Visit 10 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Physical Functioning : Visit 1 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Physical Functioning : Visit 5 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Physical Functioning : Visit 8 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Physical Functioning : Visit 9 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Physical Functioning : Visit 10 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-physical : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-physical : Visit 5 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-physical : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-physical : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-physical : Visit 10 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-emotional : Visit 1 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-emotional : Visit 5 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-emotional : Visit 8 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-emotional : Visit 9 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Role-emotional : Visit 10 | 33.33 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Energy/fatigue : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Energy/fatigue : Visit 5 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Energy/fatigue : Visit 8 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Energy/fatigue : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Energy/fatigue : Visit 10 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Emotional Well-being : Visit 1 | 72 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Emotional Well-being : Visit 5 | 76 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Emotional Well-being : Visit 8 | 68 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Emotional Well-being : Visit 9 | 64 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Emotional Well-being : Visit 10 | 68 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Social Functioning : Visit 1 | 12.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Social Functioning : Visit 5 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Social Functioning : Visit 8 | 37.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Social Functioning : Visit 9 | 12.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Social Functioning : Visit 10 | 12.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Pain : Visit 1 | 22.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Pain : Visit 5 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Pain : Visit 8 | 22.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Pain : Visit 9 | 32.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: Pain : Visit 10 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: General Health : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: General Health : Visit 5 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: General Health : Visit 8 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: General Health : Visit 9 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #5: General Health : Visit 10 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Physical Functioning : Visit 1 | 22.22 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Physical Functioning : Visit 5 | 27.78 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Physical Functioning : Visit 8 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Physical Functioning : Visit 9 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Physical Functioning : Visit 10 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-physical : Visit 1 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-physical : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-physical : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-physical : Visit 10 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-emotional : Visit 1 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-emotional : Visit 8 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-emotional : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Role-emotional : Visit 10 | 33.3 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Energy/fatigue : Visit 1 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Energy/fatigue : Visit 5 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Energy/fatigue : Visit 8 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Energy/fatigue : Visit 9 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Energy/fatigue : Visit 10 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Emotional Well-being : Visit 1 | 46.67 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Emotional Well-being : Visit 5 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Emotional Well-being : Visit 8 | 64 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Emotional Well-being : Visit 9 | 64 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Emotional Well-being : Visit 10 | 36 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Social Functioning : Visit 1 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Social Functioning : Visit 8 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Social Functioning : Visit 9 | 37.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Social Functioning : Visit 10 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Pain : Visit 1 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Pain : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Pain : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: Pain : Visit 10 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: General Health : Visit 1 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: General Health : Visit 5 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: General Health : Visit 8 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: General Health : Visit 9 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #6: General Health : Visit 10 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Physical Functioning : Visit 1 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Physical Functioning : Visit 5 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Physical Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Physical Functioning : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Physical Functioning : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-physical : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-physical : Visit 5 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-physical : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-physical : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-physical : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-emotional : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-emotional : Visit 5 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-emotional : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-emotional : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Role-emotional : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Energy/fatigue : Visit 1 | 65 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Energy/fatigue : Visit 5 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Energy/fatigue : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Energy/fatigue : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Energy/fatigue : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Emotional Well-being : Visit 1 | 72 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Emotional Well-being : Visit 5 | 88 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Emotional Well-being : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Emotional Well-being : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Emotional Well-being : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Social Functioning : Visit 1 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Social Functioning : Visit 5 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Social Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Social Functioning : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Social Functioning : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Pain : Visit 1 | 77.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Pain : Visit 5 | 77.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Pain : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Pain : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: Pain : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: General Health : Visit 1 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: General Health : Visit 5 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: General Health : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: General Health : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #7: General Health : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Energy/fatigue : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Energy/fatigue : Visit 8 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Energy/fatigue : Visit 9 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Energy/fatigue : Visit 10 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Emotional Well-being : Visit 1 | 56 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Emotional Well-being : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Emotional Well-being : Visit 8 | 64 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Emotional Well-being : Visit 9 | 52 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Emotional Well-being : Visit 10 | 92 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Social Functioning : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Social Functioning : Visit 8 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Social Functioning : Visit 9 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Social Functioning : Visit 10 | 62.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 Pain : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 General Health : Visit 1 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 General Health : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 General Health : Visit 8 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 General Health : Visit 9 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #14 General Health : Visit 10 | 60 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Physical Functioning : Visit 1 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Physical Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Physical Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Physical Functioning : Visit 9 | 5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Physical Functioning : Visit 10 | 11.11 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-physical : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-physical : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-physical : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-physical : Visit 10 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-emotional : Visit 1 | 66.67 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-emotional : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-emotional : Visit 9 | 66.67 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Role-emotional : Visit 10 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Energy/fatigue : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Energy/fatigue : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Energy/fatigue : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Energy/fatigue : Visit 9 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Energy/fatigue : Visit 10 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Emotional Well-being : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Emotional Well-being : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Emotional Well-being : Visit 9 | 88 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Emotional Well-being : Visit 10 | 80 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Social Functioning : Visit 1 | 37.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Social Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Social Functioning : Visit 9 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Social Functioning : Visit 10 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Pain : Visit 1 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Pain : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Pain : Visit 9 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 Pain : Visit 10 | 22.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 General Health : Visit 1 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 General Health : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 General Health : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 General Health : Visit 9 | 15 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #15 General Health : Visit 10 | 10 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Physical Functioning : Visit 1 | 30 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Physical Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Physical Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Physical Functioning : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Physical Functioning : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-physical : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-physical : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-physical : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-physical : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-physical : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-emotional : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-emotional : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-emotional : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Role-emotional : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Energy/fatigue : Visit 1 | 20 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Energy/fatigue : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Energy/fatigue : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Energy/fatigue : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Energy/fatigue : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Emotional Well-being : Visit 1 | 48 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Emotional Well-being : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Emotional Well-being : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Emotional Well-being : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Emotional Well-being : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Social Functioning : Visit 1 | 0 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Social Functioning : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Social Functioning : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Social Functioning : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Pain : Visit 1 | 22.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Pain : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Pain : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 Pain : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 General Health : Visit 1 | 25 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 General Health : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 General Health : Visit 8 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 General Health : Visit 9 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #16 General Health : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Physical Functioning : Visit 1 | 95 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Physical Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Physical Functioning : Visit 8 | 88.89 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Physical Functioning : Visit 9 | 85 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Physical Functioning : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-physical : Visit 1 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-physical : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-physical : Visit 9 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-physical : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-emotional : Visit 1 | 66.67 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-emotional : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-emotional : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-emotional : Visit 9 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Role-emotional : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Energy/fatigue : Visit 1 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Energy/fatigue : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Energy/fatigue : Visit 8 | 40 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Energy/fatigue : Visit 9 | 35 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Energy/fatigue : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Emotional Well-being : Visit 1 | 96 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Emotional Well-being : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Emotional Well-being : Visit 8 | 76 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Emotional Well-being : Visit 9 | 76 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Emotional Well-being : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Social Functioning : Visit 1 | 87.5 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Social Functioning : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Social Functioning : Visit 8 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Social Functioning : Visit 9 | 50 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Social Functioning : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Pain : Visit 1 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Pain : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Pain : Visit 8 | 100 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Pain : Visit 9 | 75 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 Pain : Visit 10 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 General Health : Visit 1 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 General Health : Visit 5 | NA Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 General Health : Visit 8 | 70 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 General Health : Visit 9 | 55 Average Score |
| Bortezomib | Short Form (SF)-36 Health Survey | Pt #17 General Health : Visit 10 | NA Average Score |